AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37638838 — intervention group
Group type: EXPERIMENTAL
Intervention: Pecan-enriched diet (68 g of pecans/day)
Number of subjects: 41
Study 37638838 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 41
Study 37638882 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of treatment options
Number of subjects: 281
Study 37638882 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of treatment options offered
Number of subjects: 281
Study 37638882 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of PAD
Number of subjects: 281
Study 37638882 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment goal rankings
Number of subjects: 281
Study 37638882 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in treatment goal importance
Number of subjects: 281
Study 37638882 — intervention group
Group type: EXPERIMENTAL
Intervention: Most important treatment goal
Number of subjects: 281
Study 37638968 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month edoxaban treatment
Number of subjects: 601
Study 37638968 — intervention group
Group type: COMPARATOR
Intervention: 3-month edoxaban treatment
Number of subjects: 601
Study 37639169 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran 0.3 mg/kg intravenously every 3 weeks for 12 months
Number of subjects: 23
Study 37639169 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran
Number of subjects: 23
Study 37639169 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran 0.3 mg/kg q3w
Number of subjects: 23
Study 37639243 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 108
Study 37639243 — intervention group
Group type: COMPARATOR
Intervention: Placebo crossover to Mavacamten
Number of subjects: 108
Study 37639259 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten (2.5 mg once daily for 30 weeks)
Number of subjects: 81
Study 37639272 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-supported care (MR-SC)
Number of subjects: 22
Study 37639272 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 22
Study 37639295 — intervention group
Group type: EXPERIMENTAL
Intervention: MeT4VeT app (full app)
Number of subjects: 50
Study 37639295 — intervention group
Group type: COMPARATOR
Intervention: Noninteractive app with signposting information (control)
Number of subjects: 50
Study 37639296 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based bodily interventions
Number of subjects: 36
Study 37639296 — intervention group
Group type: COMPARATOR
Intervention: Smartphone-based fairy tale interventions (control)
Number of subjects: 36
Study 37639296 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention types
Number of subjects: 36
Study 37639299 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Worlds (VW) training
Number of subjects: 0
Study 37639299 — intervention group
Group type: COMPARATOR
Intervention: Asynchronous web-based PTSD training
Number of subjects: 0
Study 37639601 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acetylcholine receptor agonist
Number of subjects: 160
Study 37639601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 37639651 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 156
Study 37639723 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy with computer-aided detection
Number of subjects: 3213
Study 37639723 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy without computer-aided detection (Control)
Number of subjects: 3213
Study 37639751 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoxygenation with forced ventilation at 8 breaths/min for 1 minute
Number of subjects: 87
Study 37639751 — intervention group
Group type: EXPERIMENTAL
Intervention: dPVi (difference in pleth variability index)
Number of subjects: 87
Study 37639751 — intervention group
Group type: EXPERIMENTAL
Intervention: %PVi (percentage of change in pleth variability index)
Number of subjects: 87
Study 37639751 — intervention group
Group type: EXPERIMENTAL
Intervention: %PVi
Number of subjects: 87
Study 37639777 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol (0.125 mg/kg to 0.24 mg/kg based on weight)
Number of subjects: 104
Study 37639777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 37639777 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol
Number of subjects: 104
Study 37639820 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 COVID-19 vaccine
Number of subjects: 1973
Study 37639820 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy or oral targeted therapy
Number of subjects: 1973
Study 37639820 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral targeted therapy
Number of subjects: 1973
Study 37639820 — intervention group
Group type: COMPARATOR
Intervention: Active cancer treatment
Number of subjects: 1973
Study 37640025 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody plus anti-vascular endothelial growth factor receptor 2 inhibitors and eribulin
Number of subjects: 0
Study 37640025 — intervention group
Group type: EXPERIMENTAL
Intervention: lipid proteomics model consisting of six metabolites
Number of subjects: 0
Study 37640025 — intervention group
Group type: EXPERIMENTAL
Intervention: treatment
Number of subjects: 0
Study 37640035 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg twice daily
Number of subjects: 3209
Study 37640035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3209
Study 37640232 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley-III cognitive scores
Number of subjects: 0
Study 37640232 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley-III language scores
Number of subjects: 0
Study 37640232 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley-III cognitive composite score cut point of 92
Number of subjects: 0
Study 37640232 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley-III language composite score cut point of 88
Number of subjects: 0
Study 37640248 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 84
Study 37640248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 37640458 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 113
Study 37640458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 113
Study 37640458 — intervention group
Group type: EXPERIMENTAL
Intervention: Single anastomosis sleeve ileal (SASI) bypass
Number of subjects: 113
Study 37640452 — intervention group
Group type: EXPERIMENTAL
Intervention: ECAP-controlled closed-loop SCS (CL-SCS)
Number of subjects: 0
Study 37640452 — intervention group
Group type: COMPARATOR
Intervention: Fixed-output open-loop SCS (OL-SCS)
Number of subjects: 0
Study 37640455 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (control)
Number of subjects: 252
Study 37640455 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical grade honey (L-Mesitran, treatment)
Number of subjects: 252
Study 37640469 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (post-tetanic count of 1-2)
Number of subjects: 100
Study 37640469 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (train-of-four count of 1-2)
Number of subjects: 100
Study 37640469 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Number of subjects: 100
Study 37640625 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100mg daily subcutaneous dose during hospitalization
Number of subjects: 120
Study 37640625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 37640679 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-NK cells
Number of subjects: 0
Study 37640679 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-Macrophages (CAR-Ms)
Number of subjects: 0
Study 37640679 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Number of subjects: 0
Study 37640679 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-Macrophages (CAR-M)
Number of subjects: 0
Study 37640781 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric QoR-15F score on postoperative day 1 (POD1)
Number of subjects: 150
Study 37640781 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-rated global recovery assessment
Number of subjects: 150
Study 37640809 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral L-citrulline supplementation (100 mg/kg/day) for 7 days
Number of subjects: 42
Study 37640809 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral L-citrulline supplementation (200 mg/kg/day) for 7 days
Number of subjects: 42
Study 37640809 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral L-citrulline supplementation (300 mg/kg/day) for 7 days
Number of subjects: 42
Study 37640809 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 42
Study 37640861 — intervention group
Group type: EXPERIMENTAL
Intervention: Natriuresis-guided therapy
Number of subjects: 310
Study 37640861 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 310
Study 37640860 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent variant vaccines
Number of subjects: 0
Study 37640860 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent variant vaccines
Number of subjects: 0
Study 37640889 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic model using baseline demographic data and serially collected blood samples and transvaginal sonographies
Number of subjects: 203
Study 37640889 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal heart rate detected before 8 weeks' gestation
Number of subjects: 203
Study 37640889 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age (≥ 35 years), insufficient crown-rump-length (CRL), mean gestational sac diameter (MSD) development, presence of bleeding
Number of subjects: 203
Study 37640889 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum biomarkers including hCG, progesterone, and estradiol
Number of subjects: 203
Study 37640889 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of maternal age, vaginal bleeding, CRL, and hCG
Number of subjects: 203
Study 37640889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonography-absent model of maternal age, bleeding, hCG, and estradiol
Number of subjects: 203
Study 37640898 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential peak early diastolic strain rate (PEDSR)
Number of subjects: 420
Study 37640898 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of PEDSR by 0.1/s
Number of subjects: 420
Study 37640898 — intervention group
Group type: EXPERIMENTAL
Intervention: PEDSR ≤ 0.485/s
Number of subjects: 420
Study 37640898 — intervention group
Group type: EXPERIMENTAL
Intervention: PEDSR added to conventional prognostic factors
Number of subjects: 420
Study 37641013 — intervention group
Group type: EXPERIMENTAL
Intervention: CEN (Central Executive Network)
Number of subjects: 17
Study 37641013 — intervention group
Group type: EXPERIMENTAL
Intervention: SN (Salience Network)
Number of subjects: 17
Study 37641013 — intervention group
Group type: EXPERIMENTAL
Intervention: DMN (Default Mode Network)
Number of subjects: 17
Study 37641013 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting-state functional connectivity of the IPL and DLPFC in the CEN
Number of subjects: 17
Study 37641013 — intervention group
Group type: EXPERIMENTAL
Intervention: CEN (at six-month follow-up)
Number of subjects: 17
Study 37641013 — intervention group
Group type: EXPERIMENTAL
Intervention: SN and DMN (at six-month follow-up)
Number of subjects: 17
Study 37641020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 123
Study 37641020 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 123
Study 37641082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage fixation
Number of subjects: 200
Study 37641082 — intervention group
Group type: COMPARATOR
Intervention: Tension band wiring
Number of subjects: 200
Study 37641122 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 31
Study 37641122 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 31
Study 37641136 — intervention group
Group type: EXPERIMENTAL
Intervention: FX06 (400 mg/d, for 5 days)
Number of subjects: 49
Study 37641136 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 49
Study 37641136 — intervention group
Group type: EXPERIMENTAL
Intervention: FX06
Number of subjects: 49
Study 37641136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 37641544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 550
Study 37641544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study 37641555 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm treatment <6 h after rupture
Number of subjects: 497
Study 37641555 — intervention group
Group type: COMPARATOR
Intervention: Aneurysm treatment 6-24 h after rupture
Number of subjects: 497
Study 37641579 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-extremity muscle strength
Number of subjects: 456
Study 37641579 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-extremity strength
Number of subjects: 456
Study 37641579 — intervention group
Group type: EXPERIMENTAL
Intervention: SVC (Slow Vital Capacity)
Number of subjects: 456
Study 37641579 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper- and lower-extremity strength
Number of subjects: 456
Study 37641579 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle strength quantified by dynamometry
Number of subjects: 456
Study 37641586 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Intradermal Acupuncture combined with SSRIs (AIA)
Number of subjects: 120
Study 37641586 — intervention group
Group type: COMPARATOR
Intervention: Sham Intradermal Acupuncture combined with SSRIs (SIA)
Number of subjects: 120
Study 37641586 — intervention group
Group type: COMPARATOR
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)-only group
Number of subjects: 120
Study 37641718 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge video visit (2-5 days postdischarge) in addition to usual care
Number of subjects: 1190
Study 37641932 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 0
Study 37641966 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with advanced DCM (LVAD/HT)
Number of subjects: 1198
Study 37641966 — intervention group
Group type: COMPARATOR
Intervention: Patients with ICD only
Number of subjects: 1198
Study 37641966 — intervention group
Group type: COMPARATOR
Intervention: Patients with neither LVAD/HT nor ICD
Number of subjects: 1198
Study 37642032 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI fractional flow reserve measurement after drug-eluting stent implantation; identified adverse clinical characteristics include age ≥65 years, diabetes, chronic kidney disease, left ventricular ejection fraction <50%; identified adverse vessel characteristics include post-PCI fractional flow reserve ≤0.80 and total stent length ≥54 mm.
Number of subjects: 2081
Study 37642035 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention designed to help participants with PAD lose weight and walk for exercise
Number of subjects: 212
Study 37642035 — intervention group
Group type: COMPARATOR
Intervention: Walking exercise alone
Number of subjects: 212
Study 37642118 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline step count
Number of subjects: 419
Study 37642118 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline dyspnoea
Number of subjects: 419
Study 37642118 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased lung function and MVPA from baseline to 2 weeks
Number of subjects: 419
Study 37642118 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline physical activity (PA) and dyspnoea
Number of subjects: 419
Study 37642160 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroTest-T2D
Number of subjects: 402
Study 37642160 — intervention group
Group type: EXPERIMENTAL
Intervention: VCTE
Number of subjects: 402
Study 37642160 — intervention group
Group type: EXPERIMENTAL
Intervention: TD-SWE
Number of subjects: 402
Study 37642160 — intervention group
Group type: COMPARATOR
Intervention: Fibrosis-4
Number of subjects: 402
Study 37642160 — intervention group
Group type: EXPERIMENTAL
Intervention: MashTest-T2D
Number of subjects: 402
Study 37642160 — intervention group
Group type: COMPARATOR
Intervention: Aspartate aminotransferase
Number of subjects: 402
Study 37642160 — intervention group
Group type: EXPERIMENTAL
Intervention: SteatoTest-T2D
Number of subjects: 402
Study 37642160 — intervention group
Group type: COMPARATOR
Intervention: Controlled attenuation parameter
Number of subjects: 402
Study 37642160 — intervention group
Group type: COMPARATOR
Intervention: Hepatorenal gradient
Number of subjects: 402
Study 37642248 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin only
Number of subjects: 156
Study 37642248 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin plus intrauterine misoprostol
Number of subjects: 156
Study 37642248 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin only
Number of subjects: 156
Study 37642285 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy (VH)
Number of subjects: 6811
Study 37642285 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic hysterectomy (LH)
Number of subjects: 6811
Study 37642285 — intervention group
Group type: COMPARATOR
Intervention: Robotic-assisted hysterectomy (RH)
Number of subjects: 6811
Study 37642285 — intervention group
Group type: COMPARATOR
Intervention: Vaginal natural orifice hysterectomy (V-NOTES)
Number of subjects: 6811
Study 37642347 — intervention group
Group type: EXPERIMENTAL
Intervention: Logotherapy-based, nurse-guided meaning attribution conversations (MACs), 7 sessions
Number of subjects: 68
Study 37642347 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 68
Study 37642608 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 2732
Study 37642625 — intervention group
Group type: EXPERIMENTAL
Intervention: Active taVNS
Number of subjects: 24
Study 37642625 — intervention group
Group type: COMPARATOR
Intervention: Sham taVNS
Number of subjects: 24
Study 37642628 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 269
Study 37642628 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management (CMM)
Number of subjects: 269
Study 37642679 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT™ periurethral adjustable balloons
Number of subjects: 13
Study 37642787 — intervention group
Group type: EXPERIMENTAL
Intervention: LDCT screening
Number of subjects: 48
Study 37642787 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-based screening
Number of subjects: 48
Study 37642966 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based prenatal care (GPNC) with 10 group-based sessions
Number of subjects: 2348
Study 37642966 — intervention group
Group type: COMPARATOR
Intervention: Individual prenatal care (IPNC)
Number of subjects: 2348
Study 37642966 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based prenatal care (GPNC) among participants with GD
Number of subjects: 2348
Study 37643290 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination HIV prevention strategies implemented at the community level
Number of subjects: 2000
Study 37643290 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level measures reflecting sexual behaviour and socio-economic make-up
Number of subjects: 2000
Study 37643290 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of detectable virus (PDV) at 2 years
Number of subjects: 2000
Study 37643290 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-level factors such as socio-economic status, AUDIT score, medical male circumcision, and certain sexual behaviours
Number of subjects: 2000
Study 37643299 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37643308 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconsultations
Number of subjects: 0
Study 37643308 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37643314 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal cell-directed immunomodulatory device (selective cytopheretic device)
Number of subjects: 2
Study 37643373 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 128
Study 37643373 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 128
Study 37643378 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus Trametinib
Number of subjects: 41
Study 37643382 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1,200 mg once every 3 weeks) combined with bevacizumab and six cycles of chemotherapy doublet
Number of subjects: 614
Study 37643382 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with bevacizumab and six cycles of chemotherapy doublet
Number of subjects: 614
Study 37643392 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly phone counseling sessions with bidirectional text messages
Number of subjects: 425
Study 37643392 — intervention group
Group type: COMPARATOR
Intervention: Weekly phone counseling sessions with unidirectional text messages
Number of subjects: 425
Study 37643414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sankofa Pediatric HIV disclosure intervention
Number of subjects: 0
Study 37643414 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 0
Study 37643414 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosed group
Number of subjects: 0
Study 37643414 — intervention group
Group type: EXPERIMENTAL
Intervention: Undisclosed group
Number of subjects: 0
Study 37643520 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 209
Study 37643520 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 209
Study 37643520 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C Q1 (≤1.76 mmol/L)
Number of subjects: 209
Study 37643520 — intervention group
Group type: COMPARATOR
Intervention: LDL-C Q2 (1.77-2.36 mmol/L)
Number of subjects: 209